Overcoming the massive and rapid death of injected donor myoblasts is the primary hurdle for successful myoblast transfer therapy (MTT), designed as a treatment for the lethal childhood myopathy Duchenne muscular dystrophy. The injection of male myoblasts into female host mice and quantification of surviving male DNA using the Y-chromosome-specific (Yl) probe allows the speed and extent of death of donor myoblasts to be determined. Cultured normal C57BL/10Sn male donor myoblasts were injected into un treated normal C57BL/10Sn and dystrophic mdx female host mice and analyzed by slot blots using a 32 Plabeled Yl probe. The amount of male DNA from donor myoblasts showed a remarkable decrease within minutes and by 1 h represented only about 10-18% of the 2.5 x 10 5 cells originally injected (designated 100%). This declined further over 1 week to approximately 1-4%. The host environment (normal or dystro phic) as well as the extent of passaging in tissue culture (early "P3" or late "PI 5-20" passage) made no difference to this result. Modulation of the host response by CD4 + /CD8 + -depleting antibodies administered prior to injection of the cultured myoblasts dramatically enhanced donor myoblast survival in dystrophic mdx hosts (15-fold relative to untreated hosts after 1 week). NK1.1 depletion also dramatically enhanced donor myoblast survival in dystrophic mdx hosts (21-fold after 1 week) compared to untreated hosts. These results provide a strategic approach to enhance donor myoblast survival in clinical trials of MTT.
INTRODUCTION
The X-linked recessive disease Duchenne muscular dystrophy (DMD) is caused by defects in the gene en coding the 427-kDa protein dystrophin, which is located beneath the sarcolemma of skeletal muscle fibers [ (31, 50, 102) ; reviewed in (9, 20) ]. The absence of a func tional dystrophin molecule in humans leads to muscle fi ber necrosis and progressive muscle weakness. The progression of the disease usually results in patients be coming wheelchair-bound by the age of 12 and death due to respiratory and/or cardiac failure by 20 years (87) . The mdx mouse is also dystrophin deficient, but does not de velop the severe pathology of DMD due to its apparent ca pacity to regenerate muscle fibers after repeated cycles of necrosis without replacement by fibrous connective tissue (15, 64, 66, 79, 86) .
Transplantation of muscle precursor cells, widely re ferred to as myoblasts, from normal donors into dystro phic host muscle is the basis of myoblast transfer ther apy (MTT). The observation that transplantation of minced muscles between mice resulted in the formation of hybrid myofibers composed of a syncytium of donor and host nuclei (63) supported the use of myoblasts grown in vitro as a cellular therapy for hereditary muscle diseases (29, 41, 46, 53, 67, 95, 96) . The aim of this cell transplantation strategy is to introduce high numbers of normal donor nuclei that have the capacity to produce dystrophin and the potential to fuse with existing dystro phic host myofibers. The resulting hybrid myofiber will therefore be able to restore a functional dystrophin mol ecule to the syncytium and maintain muscle fiber integ rity (65, 67, 90) . Ideally, MTT would involve the survival of individual normal donor myoblasts after injection (followed by their replication and migration from the site), fusion with dystrophic host myofibers, and suc Major clinical trials were carried out on DMD pa tients in North America and Italy, but have widely been accepted as unsuccessful (26, 57, 89, 90) . Nevertheless, subsequent studies using animal models have yielded vi tal information about the limitations, as well as the po tential, of MTT.
While MTT has been successfully demonstrated in animal models, the vast majority of early studies were conducted using conditions that were not comparable to those in the clinical MTT trials (26) . For example, myo blasts were injected into either immunocompromised or immunodeficient mice that were unable to mount an im mune response (16, 56, 67) ; into immunocompatible hosts (52, 53) ; into host muscle that had been preirradiated, thereby impairing host myoblast proliferation and pref erentially exaggerating the contribution made by donor myoblasts (33, 58) . In other situations, the conditions used in animal studies could potentially be applied clini cally, such as transplantation into tolerized hosts (96, 97) , or into hosts that were immunosuppressed (33, 40, 49, 80, 95) . The rejection of organ and tissue grafts is widely known to be prevented by the use of powerful immunosuppressants. FK506 and its analogue rapa mycin have been used successfully to prevent the rejec tion of donor myoblasts in MTT (47, 49, 92) , and contin uous use of cyclosporin A prolongs myoblast survival, although rapid rejection results if withdrawn even 4 weeks after transplantation (39, 100) . The use of mono clonal antibodies that deplete specific T-cell subsets is an attractive alternative to the continued use of such drugs that have deleterious side effects (77) . Depleting antibodies have been shown to induce long-term toler ance to MHC mismatched grafts after withdrawal of im munosuppressive treatment (93) , and it is known that CD4 + and CD8 + T cells are essential in allograft rejec tion (13, 61, 94) . The importance of CD4 + and CD8 + Tcell depletion has been shown in the prolonged longterm survival of sliced muscle grafts implanted into mdx host mice (22, 81) . CD4 + and CD8 + T cells have also been observed in dystrophic (mdx) muscle (1, 19, 84) and have been attributed a role in the rejection of donor myo blasts in MTT (8) . Pure myogenic cell lines (such as C2C12) have also been used in many studies. These cells can move readily throughout host muscle and fuse with host myofibers. However, they differ from primary cultures of myoblasts in that they are transformed cells that have the propensity to form tumors in vivo, and their growth requirements and proliferation in vitro are different (3, 18, 38, 45, 59, 74, 99) .
The major obstacle to the success of MTT is donor myoblast survival. After injection into the host, cultured donor myoblasts undergo rapid and massive cell death. This was shown to be extensive by 2 days (23, 75) and is now known to occur even more rapidly (4) (5) (6) 72) . Nu merous studies in animal models attribute this to the host immune response, although the exact mechanism involved is not yet known. The rapid and massive cell death of cultured donor myoblasts after injection is in marked contrast with the excellent long-term survival (up to 1 year) of donor myoblasts using intact or sliced muscle grafts implanted into "untreated" dystrophic mdx hosts (21, 22, 81, 82) , which points to a crucial role for cell isolation and culture in the death of the transplanted cells.
Whether freshly cultured donor myoblasts have a sig nificantly different potential for survival and successful fusion after injection into host mdx muscle than myo blasts passaged numerous times in culture, or indeed myoblasts taken from stored frozen stocks, has not yet been quantitatively assessed. Myoblasts are grown in culture in order to expand the numbers for injection and so the requirement of even a small amount of time in culture is unavoidable. Reliable procedures have been developed for growing primary cultures of myoblasts in vitro (74, 98) and show an enrichment for the percentage of myogenic cells with time (since contaminating fibro blasts decrease with time). Culture conditions them selves (such as media components and serum factors) may alter the antigenicity of the donor myoblasts (8, 37) , and contaminating fibroblasts may compound any im mune response mounted by the host because they ex press a large amount of MHC class II antigens (44, 71) .
Finally, the origin of donor myogenic cells used for primary culture may influence their survival after injec tion into host muscle. The analysis of myoblast popula tions from limb and masseter muscles shows an in creased regenerative capacity in vivo and a faster growth rate in vitro for limb-derived myoblasts (68) . Different myoblast populations isolated from fast and slow twitch muscle fibers may also follow a preferential difference in fate after injection (35, 72, 73) .
This study uses a Y-chromosome-specific probe (62) to quantify the survival of male donor myoblast into muscles of female host mice. It compares: a) the sur vival in untreated normal versus dystrophic mdx host mice, b) early versus late passage-cultured myoblasts, and c) dystrophic hosts depleted of CD4 + /CD8 + T cells and NK1.1 + cells (regimes designed to modulate the host response). The answers to these fundamental questions provide a strong foundation upon which to develop strat egies designed to enhance MTT in the clinical situation.
MATERIALS AND METHODS

Animals
Mdx mice were obtained from the Australian Neuro muscular Research Institute. C57BL/10Sn (the normal parental strain for mdx) were obtained from the Animal Resource Centre, Western Australia. All animal proce-dures were carried out in strict accordance with National Health and Medical Research Council of Australia guidelines.
Tissue Culture
Skeletal muscles were taken from the hind limbs and lower back of 4-6-week-old donor male C57BL/10Sn mice. Myoblasts were isolated from these muscles by enzymic digestion and filtration through 100-pm nylon gauze as described previously (23, 54) . The resulting pri mary culture was maintained in Hams F10 medium (Trace) supplemented with 20% (v/v) fetal calf serum (FCS) (Trace), 4 mM L-glutamine (Sigma), 100 IU/ml penicillin, 100 pg streptomycin (Sigma), and 25 ng/ml basic fibroblast growth factor (bFGF) (Synergen). Me dium was replaced every other day and cells were grown to 70-80% confluency before harvesting by digestion with 0.1% (w/v) trypsin (ICN-Flow). Cells were reseeded at approximately 1-2 x 10 5 cells per 75-cm 2 flask [precoated with 1% (w/v) gelatin] in fresh medium and passaged successively in this way. Fresh primary cul tures (up to 3 passages) or late passage (15-20 passages) were also fixed with 4% (w/v) paraformaldehyde and subjected to immunocytochemistry using an anti-desmin polyclonal antibody (BioGenex) followed by detection with a rabbit anti-mouse IgG horseradish peroxidaseconjugated secondary antibody (Dakopatts) and o-phenylenediamine or 4-chloro-naphthol substrate in order to estimate the percentage of myoblasts within the popula tion.
Myoblast Injection
Either fresh primary cultures (P3) or late passage cultures were adjusted to a concentration of 2.5 x 10 5 /10 pi in phosphate-buffered saline (PBS, pH 7.2) and kept on ice. Ten microliters of this cell suspen sion was injected longitudinally into each tibialis ante rior (TA) of 6-8-week-old female host mice using a Hamilton syringe with a 29-gauge needle. The needle was retracted carefully as the cells were injected in order to minimize the physical trauma of injection. Host mice used for 0 h time points were injected after surgically exposing the TA muscle, so that the sample was ready for immediate removal.
Immunodepletion CD4*/CD<? Depletion.
Host mice were injected IP with 100 pi (15 mg) of each neat monoclonal antibody (in serum-free medium) over a period of 5 days prior to MTT, in order to deplete the host of CD4 + and CD8 + cells. The YTS191 (rat anti-mouse CD4 + ) and YTS169 (rat anti-mouse CD8 + ) antibodies, both kindly provided by Dr. T. Scalzo (Dept. of Microbiology, UWA), were injected on day -5, day -3, and day -1, as well as a final injection at least 4 h (day 0) before MTT.
FACS Analysis.
In order to confirm that mdx host The massive initial death of injected donor myoblasts could therefore not be readily attributed to leakage of injected myoblasts from the site of injection.
Effect of CD4 + /CD8 + T-Cell Depletion in mdx Host Mice
Prior to analyzing the effect of leukocyte depletion on the survival of transplanted myoblasts, assays for the effectiveness of T-cell depletion were carried out. FACS analysis of the spleens of mdx hosts showed that there was effective depletion (approximately 80-90%) of CD4 + and CD8 + T cells in these animals prior to injec tion of normal donor male myoblasts (Fig. 5 ). However, 
Survival of Late Passage Donor Myoblasts in CD4 + / CDS'-Depleted mdx Host Mice
There was a dramatic increase in survival of donor myoblasts after injection into dystrophic female hosts pretreated with anti-CD4 + and anti-CD8 + antibodies. The results are shown in Figure 6 and also summarized in Table 1 . In CD4 + /CD8 + -depleted hosts there was nearly a threefold increase in average donor myoblast survival at 0 h (to 43.3% from 15.8%) compared with untreated hosts. At 4 h after injection, the difference was fivefold (to 25.7% from 4.8%) and after 24 h it was eightfold (to 16.8% from 2.1%). At 48 h the difference was 24-fold (to 16.8% from 0.7%) and by 1 week there was still an eightfold increase in average donor myoblast survival (to 14.7% from 1.8%). There was considerable variation between samples in each treated group, although AN OVA analysis showed that there was significant differ ence {p < 0.05) of donor myoblast survival between CD47CD8 + -depleted and untreated host mice at 0 h, 48 h, and after 1 week. The significant decrease in numbers of donor male myoblasts in CD4 + /CD8 + -depleted mdx hosts over 1 week suggests that although antibody depletion did increase donor myoblast survival initially, it was not effective at sustaining this.
Effect ofNKJ.T Cell Depletion in mdx Host Mice
Prior to analyzing the effect of leukocyte depletion on the survival of transplanted myoblasts, assays for the effectiveness of NK1. depletion of cytotoxic activity, with average 5l Cr release values indicating a range of only 5-14% above sponta neous control levels at 0 h. Using splenocytes isolated from mdx hosts at 1 week (168 h) after depletion, aver age 51 Cr release values ranged from 77% to 87% of those obtained from control (undepleted) mdx spleno cytes (data not shown).
Survival of Late Passage Donor Myoblasts in NKl.t-Depleted mdx Host Mice
There was also a dramatic increase in survival of do nor myoblasts after injection into dystrophic mdx female hosts pretreated with antibody depletion of NK1.1 + cells.
Again, the results are shown in Figure 6 and summa rized in the present study. The differences between the two stud ies are restricted to time 0 only and data for all later time points agree. We consider that the massive initial loss of injected donor myoblasts is due to cell death, but cannot exclude the possibility that some "undetectable" leakage may have occurred. However, every care was taken to minimize leakage including trial injection into TA muscles where the skin was opened and no leakage was observed. Furthermore, only small variations were seen between multiple samples for each time point, plus the antibody depletion regimes "rescued" myoblasts from the initial "death," which argues strongly against significant leakage.
Viability assays before and after injection of donor myoblasts back into tissue culture confirmed that the process of injection through the needle itself did not re sult in cell death. Comparable levels of cell death have also been observed in donor myoblasts that were trans planted into host muscles within fibrin clots (6) that Standard deviation shown in parentheses; n = 4 at 0 h and n = 6 for all other time points.
avoided the potential trauma of injection in vivo. Myo blast death was not considered to be apoptotic, because electron microscopy showed no evidence of extensive condensed chromatin or nuclear blebbing of donor myo blasts in TA muscle sections taken at 0, 1, 4, and 24
h after injection (data not shown). Furthermore, DNA isolated from injected TA muscles did not show any DNA laddering characteristic of apoptosis (17, 88) after electrophoresis in agarose gels (data not shown).
Our data strongly suggest that it is the process of iso lation of donor myoblasts from skeletal muscles, or ex posure of these myoblasts to tissue culture conditions (83) , that renders them susceptible to this rapid and mas sive cell death after transfer to the in vivo environment.
The significantly better survival of donor male myo blasts when slices of donor muscle (rather than isolated cultured myoblasts) are transplanted (21, 23, 81) is inter esting to note in this context.
Survival of Early vs. Late Passage Myoblasts
There is essentially no difference in the survival of early (P3) or late (PI5-20) passage donor myoblasts after injection, suggesting that, at least in these experi ments, the length of time spent by donor myoblasts in tissue culture is not critical to their initial survival after transplantation. However, there appears to be a slight repopulation of early passage (P3) myoblasts in both C57BL/10Sn and mdx hosts between 48 h and 1 week after injection, which may be due to proliferation of these cells. This is in accord with the results of Beau champ et al. (4) , which showed a slight increase in male donor myoblast (using the Yl probe as a measurement of Y chromosome content) from 48 to 96 h after trans plantation. This is important, as it is often convenient to use cultures that have been expanded over many pas sages as the source of donor myoblasts in MTT experi ments. However, there may be long-term consequences for the capacity of myoblast replication after extended passaging in culture, because nearly 4% of early passage donor myoblasts survived after 1 week compared to 1 % of late passage donor myoblasts, in both normal and dystrophic hosts. If, indeed, expansion of myoblast pop ulations in tissue culture does subsequently restrict their capacity to proliferate in vivo (after injection), this ar gues strongly against their use in clinical trials. Ex tended time in tissue culture may also lead to transfor mation of mouse myoblasts, resulting in the formation of aberrant muscle tissue and/or tumors after transplan tation in vivo (T. Partridge, personal communication).
Preliminary data using frozen stocks of early and late passage myoblasts show no difference in the percentage of donor myoblast survival between frozen and nonfro zen stocks after injection into normal or dystrophic host mice, even after approximately 25 passages in culture (S. Hodgetts, unpublished results). It is important to know that there are apparently no adverse effects associ ated with freezing myoblasts, as some MTT experiments may use large numbers of donor myoblasts that can be conveniently accumulated and frozen until required and then pooled for injection.
Manipulation of the Host Immune Response
Depletion of Host CD4 + and CDS' T Cells. Dystro phic female mdx hosts depleted of CD4 + and CD8 + T cells showed an improved (threefold) survival of cul tured injected donor male myoblasts immediately after injection. Although the average percentage of surviving myoblasts decreased with time in CD4 + /CD8 + -depleted hosts, after 1 week there was still an eightfold increase in survival compared to myoblasts transplanted into un treated control hosts. These results suggest that CD4 + and CD8 + T cells play a role in myoblast survival after transplantation.
Activation of CD4 + T cells generally leads to the pro duction of cytokines that are extremely effective immunoregulatory molecules, while activation of CD8 + T cells leads to cytotoxic activity [reviewed in (30, 85) ]. CD4 + and CD8 + T cells recognize foreign antigens via an asso ciation with class II and class I major histocompatibility complex (MHC) molecules, respectively, and this inter action is required for processing and subsequent T-cell activation. The importance of CD4 + and CD8 + T-cell depletion has been shown in the prolonged long-term survival of donor myoblasts that have migrated out of sliced muscle grafts implanted into mdx host mice (22, 82) . A role for T cells is also supported by the success of MTT experiments performed in immunocom promised or immunodeficient (16, 56, 67) , immunosup pressed (33, 40, 48, 69, 95) , and tolerized host mice (96, 97) .
Our data show that CD4 + and CD8 + T-cell depletion was not 100% complete in the spleen compared to that reported by Spencer et al. (84) for CD8 + depletion in mdx mice. Blocking antibodies may also be required to affect total CD4 + and CD8 + T-cell depletion (12, 14) . However, our data show that CD4 + /CD8 + depletion (even if incomplete) dramatically enhanced donor myo blast survival after injection. The repopulation of CD4 + and CD8 + T cells after their initial depletion also sug gests that they might continue to be involved in donor myoblast death for up to 3 weeks after injection, as the reemergence of normal numbers of CD4 + and CD8 + T cells mirrors the continuing decline in surviving donor male myoblasts. It seems likely that, even if CD4 + and CD8 + T cells are not the main effector of the host immune response, their contribution to pro-inflamma tory cytokine production would have an important and marked influence on the survival of cultured donor myoblasts. Our data suggest that complete depletion of these cells may be required to sustain the enhanced long-term survival of donor myoblasts after injection. cytokine production as major effector mechanisms (7) . cells to secrete interferon-y (10, 60) . NK cells recognize target cells via a mechanism involving several surface receptors that are responsible for activation in a poorly understood combination with receptors specific for MHC class I molecules that inhibit their activity (51, 101) . NK cells have also been reported to participate in xenogeneic organ rejection and are found at high fre quency in cellular infiltrates associated with xenograft rejection (2, 24, 43, 91) . NK cell depletion in combination with immunosuppression has been found to slightly pro long xenograft survival, although at least one study sug gested that IL2 production by T cells may also be re quired [reviewed in (2) ].
Dendritic cells (DC) have also been shown to express the NK cell receptor protein 1, express NK1.1, and to possess cytotoxic activity (42, 55, 76, 78) . DC are resident in skeletal muscle (70) and their major function is pro cessing exogenous antigen for MHC class I and II pre sentation (78) . The significance of potential NK1.1 ex pression on DC within skeletal muscle and the enhanced donor myoblast survival following NK1.1 depletion is unclear at this stage.
Transient immunosuppression with monoclonal anti bodies to ICAM-1 and LFA-1 has been shown to in crease the retention of allogeneic myoblasts up to 4 months after MTT (69) . Similarly, donor myoblast sur vival (100% was measured by (3-Gal staining at 1 h after MTT) was also enhanced for up to 1 month using anti-LFA-1 antibody to modify the inflammatory reaction that accompanies MTT (28) . LFA-1 is an adhesion mol ecule present on the surface of neutrophils, macro phages, NK cells, and lymphocytes (27) . The inflamma tory reaction after MTT was characterized by a massive infiltration of neutrophils; basophils, eosinophils, LFA-
1-positive cells, and MAC-T cells (macrophages and
NK cells) (27) . In addition, cytotoxic T cells and NK cells have been shown to rapidly damage developing myotubes (32) . It is also of interest that monoclonal anti bodies to NK cells react with neural cell adhesion mole cule (N-CAM), which is a surface glycoprotein present in muscle satellite cells and regenerating or newly de nervated muscle fibers (36) . surface, or those that lack them entirely, are quickly de stroyed by NK cells (11) . Perhaps NK cells are activated to destroy myoblasts because of an alteration of class I MHC expression on their surface as a direct conse quence of their exposure to tissue culture conditions. It is tempting to speculate that the generation of neoantigens on myoblasts due to tissue culture conditions (37) might cause an aberrant recognition of class I MHC by NK cell receptors, followed by their subsequent activa tion and the destruction of donor myoblasts.
Long-term studies are in place to confirm the impact of each of these depletion strategies for optimizing the success of MTT. 
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